Clinical cancer vaccine trials
- 20 February 2002
- journal article
- review article
- Published by Elsevier in Current Opinion in Immunology
- Vol. 14 (2) , 178-182
- https://doi.org/10.1016/s0952-7915(02)00318-7
Abstract
No abstract availableKeywords
This publication has 34 references indexed in Scilit:
- Immunogenicity of nonreplicating recombinant vaccinia expressing HLA-A201 targeted or complete MART-1/Melan-A antigenCancer Gene Therapy, 2001
- Evaluation of peptide vaccine immunogenicity in draining lymph nodes and peripheral blood of melanoma patientsInternational Journal of Cancer, 2001
- Tumor Eradication by Wild-type p53-specific Cytotoxic T LymphocytesThe Journal of Experimental Medicine, 1997
- Human papillomarivus vaccines for cervical cancerCurrent Opinion in Immunology, 1996
- A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas.The Journal of Experimental Medicine, 1994
- Identification of a Peptide Recognized by Five Melanoma-Specific Human Cytotoxic T Cell LinesScience, 1994
- Frequency analysis of tumor-reactive cytotoxic T lymphocytes in peripheral blood of a melanoma patient vaccinated with autologous tumor cellsCancer Immunology, Immunotherapy, 1994
- Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes.The Journal of Experimental Medicine, 1994
- The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas.The Journal of Experimental Medicine, 1993
- A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human MelanomaScience, 1991